Olinger Margaret 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Dec 29, 2023
Insider Transaction Report
Form 4
Olinger Margaret
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-12-27$0.37/sh+25,000$9,250→ 276,108 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-27−25,000→ 44,577 totalExercise: $0.37Exp: 2029-05-13→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option are fully vested and exercisable.